Monica Lispi

Dr. Monica Lispi

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
MLMonica Lispi
Monica Lispi
PHPeter Humaidan
Peter Humaidan
GBGeorge R. Bousfield
George R. Bousfield
TDThomas D'Hooghe
Thomas D'Hooghe
AUAlfredo Ulloa-Aguirre
Alfredo Ulloa-Aguirre
Follicle-stimulating hormone (FSH), together with luteinizing hormone (LH) and human chorionic gonadotropin (hCG), plays a fundamental role in human reproduction. The discovery of FSH and other gonadotropins was a defining moment in our understanding of reproduction and led to the development of many treatments for infertility. In this regard, exogenous FSH has been used to treat infertility in women for decades. Today, several recombinant and highly purified urinary forms of FSH are used in medically assisted reproduction (MAR). However, differences in the macro- and micro-heterogeneity of FSH result in a variety of FSH glycoforms, with glycoform composition determining the bioactivity (or potency), pharmacokinetic/pharmacodynamic (PK/PD) profiles, and clinical efficacy of the different forms of FSH. This review illustrates how the structural heterogeneity of FSH glycoforms affects the biological activity of human FSH products, and why potency does not predict effects in humans in terms of PK, PD, and clinical response.

17 October 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
MLMonica Lispi
Monica Lispi
Panagiotis DrakopoulosPanagiotis Drakopoulos
Panagiotis Drakopoulos
GSGiorgia Spaggiari
Giorgia Spaggiari
FCFrancesca Caprio
Francesca Caprio
NCNicola Colacurci
Nicola Colacurci
DSDaniele Santi
Daniele Santi
Purpose: Although a robust physiological rationale supports follicle stimulating hormone (FSH) use in male idiopathic infertility, useful biomarkers to evaluate its efficacy are not available. Thus, the primary aim of the study was to evaluate if testosterone serum levels are related to sperm DNA fragmentation (sDF) index change after FSH administration. The secondary aim was to confirm sDF index validity as a biomarker of FSH administration effectiveness in male idiopathic infertility. Methods: A retrospective, post-hoc re-analysis was performed on prospectively collected raw data of clinical trials in which idiopathic infertile men were treated with FSH and both testosterone serum levels and sDF were reported. Results: Three trials were included, accounting for 251 patients. The comprehensive analysis confirmed FSH’s beneficial effect on spermatogenesis detected in each trial. Indeed, an overall significant sDF decrease (p < 0.001) of 20.2% of baseline value was detected. Although sDF resulted to be unrelated to testosterone serum levels at baseline, a significant correlation was highlighted after three months of FSH treatment (p = 0.002). Moreover, testosterone serum levels and patients’ age significantly correlated with sDF (p = 0.006). Dividing the cohort into responders/not responders to FSH treatment according to sDF change, the FSH effectiveness in terms of sDF improvement was related to testosterone and male age (p = 0.003). Conclusion: Exogenous FSH administration in male idiopathic infertility is efficient in reducing sDF basal levels by about 20%. In terms of sDF reduction, 59.2% of the patients treated were FSH-responders. After three months of FSH administration, a significant inverse correlation between sDF and testosterone was detected, suggesting an association between the FSH-administration-related sDF improvement and testosterone serum levels increase. These observations lead to the hypothesis that FSH may promote communications or interactions between Sertoli cells and Leydig cells.

Verified
Journal Article
Open access
PDF file
LMLucio Manzi
Lucio Manzi
NSNunzio Sepe
Nunzio Sepe
WMWalter Migliaccio
Walter Migliaccio
LLLudovica Lanzoni
Ludovica Lanzoni
LILuisa Iozzino
Luisa Iozzino
MLMonica Lispi
Monica Lispi
Although the full primary structures of the alfa and beta subunits of reference r-hFSH-alfa and its biosimilars are identical, cell context-dependent differences in the expressing cell lines and manufacturing process can lead to variations in glycosylation profiles. In the present study, we compared the structural features of reference r-hFSH-alfa with those of five biosimilar preparations approved in different global regions outside Europe (Primapur®, Jin Sai Heng®, Follitrope®, Folisurge®, and Corneumon®) with respect to glycosylation, macro- and microheterogeneity, and other post-translational modifications and higher order structure. The mean proportion of N-glycosylation-site occupancy was highest in reference r-hFSH-alfa, decreasing sequentially in Primapur, Jin Sai Heng, Corneumon, Follisurge and Follitrope, respectively. The level of antennarity showed slightly higher complexity in Corneumon, Primapur and Follitrope versus reference r-hFSH-alfa, whereas Jin Sai Heng and Folisurge were aligned with reference r-hFSH-alfa across all N-glycosylation sites. Sialylation level was higher in Corneumon and Follitrope, but small differences were detected in other biosimilar preparations compared with reference r-hFSH-alfa. Jin Sai Heng showed higher levels of N-glyconeuramic acid than the other preparations. Minor differences in oxidation levels were seen among the different products. Therefore, in summary, we identified var ious differences in N-glycosylation occupancy, antennarity, sialylation and oxidation between reference r-hFSH-alfa and the biosimilar preparations analyzed.

2 September 2015 in Journal of Cellular Physiology
Verified
Journal Article
Open access
PDF file
Carla TatoneCarla Tatone
Carla Tatone
EBElisabetta Benedetti
Elisabetta Benedetti
MVMaurizio Vitti
Maurizio Vitti
Giovanna Di EmidioGiovanna Di Emidio
Giovanna Di Emidio
RCRosanna Ciriminna
Rosanna Ciriminna
O(on Behalf of Italian Society of Embryology, Reproduction and Research (SIERR)
on Behalf of Italian Society of Embryology, Reproduction and Research (SIERR)
Controlled ovarian stimulation (COS) leading to ovulation of multiple follicles is a crucial aspect of biomedical infertility care. Nevertheless, biomarkers useful for COS management are still lacking. Peroxisome proliferator‐activated receptors (PPARs) are nuclear hormone receptors relevant to steroid metabolism in granulosa cells (GCs). We investigated whether PPARs and their steroidogenic targets were differentially expressed in GCs differentiated under different recombinant or urinary gonadotropin preparations. GCs from women subjected to COS with r‐hFSH, r‐hFSH/r‐hLH, or hMG‐HP were processed to assess expression of PPARα, PPARβ/δ, PPARγ, and steroidogenic enzymes under PPAR modulation. As an evidence of their activation, all PPAR isotypes with their coactivators, the retinoic‐X‐receptors (RXRs), localized in the nucleus. When GCs from r‐hFSH/r‐hLH group were compared with r‐hFSH, a significant reduction of PPARα protein was observed. By contrast, an increase of PPARβ/δ at both protein and mRNA levels along with that of PPARγ protein were detected. The steroidogenic enzymes 17βHSD IV, 3βHSD II, and HMG‐CoA red were downregulated in the r‐hFSH/r‐hLH group in comparison to r‐hFSH unlike CYP19A1 that remained unchanged. In GCs from urinary FSH‐LH stimulation (hMG‐HP), PPARα was more expressed in comparison with r‐hFSH/r‐hLH group. Likewise, 3βHSD II and 17βHSD IV were increased suggesting that hMG‐HP partially mimicked r‐hFSH/r‐hLH effects. In summary, transcript analysis associated to protein investigation revealed differential effects of COS protocols on PPARs and their steroidogenic targets in relation to LH and gonadotropin source. These observations candidate PPARs as new biomarkers of follicle competence opening new hypotheses on COS effects on ovarian physiology. J. Cell. Physiol. 231: 908–914, 2016.

Verified
Journal Article
Open access
PDF file
FNFrancesco Nevelli
Francesco Nevelli
APAngelo Palmese
Angelo Palmese
RGRalf Gleixner
Ralf Gleixner
FPFlavio Peroglio
Flavio Peroglio
CDCosimo-Walter D’acunto
Cosimo-Walter D’acunto
MLMonica Lispi
Monica Lispi
Various preparations of follicle-stimulating hormone (FSH) are commercially available; however, they differ in glycoforms composition and purity owing to their respective sources. Additional chemical/physical changes can also be introduced during manufacturing and can impact their biological activity (biopotency), which is routinely assessed using an in vivo bioassay (Steelman–Pohley). This study aimed to determine whether an in vitro bioassay could assess biopotency by distinguishing between r-hFSH chemical/physical variants with similar ability to the in vivo bioassay. The specific activity (units of biological activity per mg of product) of variants of r-hFSH generated through enrichment (acidic/basic), stress (oxidative/acidic pH) and enzymatic treatment (desialylation and desialylation/degalactosylation) was compared using the in vivo and in vitro bioassays. The in vitro bioassay reliably detected potential chemical/physical modifications in r-hFSH variants that may impact biopotency. Overall, the methods demonstrated a comparable ability to detect changes in specific activities due to chemical/physical differences in r-hFSH variants. These data indicate that the in vitro bioassay is suitable to replace the in vivo bioassay.

2 February 2022 in Best Practice & Research Clinical Obstetrics & Gynaecology
Verified
Journal Article
Open access
ALAcco Luyten
Acco Luyten
MCMark Connolly
Mark Connolly
EVEvelyn Verbeke
Evelyn Verbeke
KBKlaus Buhler
Klaus Buhler
GSGraham Scotland
Graham Scotland
TDThomas D'Hooghe
Thomas D'Hooghe
Economic evaluations of the value-for-money of Medically Assisted Reproduction (MAR) interventions are increasingly important due to growing pressure on healthcare budgets. Although such evaluations are commonplace in the published literature, the number/methodological complexity of different evaluations available, and the challenges specific to MAR interventions, can complicate the interpretation of such analyses for fertility treatments. This article aims to serve as an educational resource and provide context on the design/interpretation of economic analyses for MAR interventions. Several areas are relevant for first-line providers and decision makers: scope of analysis, comparator used, perspective/time horizon considered, outcomes used to measure success, and how results from cost-effectiveness studies can be summarised and used in clinical practice. We aim to help clinicians better understand the strengths/weaknesses of economic analyses, to enable the best use of the evidence in practice, so resources available for MAR interventions can provide maximum value to patients and society.